BIOMAT Database Logo BIOMAT Database Logo

Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension. 1995

A H van den Meiracker, and P J Admiraal, and J A Janssen, and J M Kroodsma, and W A de Ronde, and F Boomsma, and J Sissmann, and P J Blankestijn, and P G Mulder, and A J Man In 't Veld
Department of Internal Medicine I, University Hospital Dijkzigt, Rotterdam, The Netherlands.

We studied the hemodynamic, neurohumoral, and biochemical effects of the novel angiotensin type 1 (AT1) receptor antagonist irbesartan in 86 untreated patients with essential hypertension on a normal sodium diet. According to a double-blind parallel group trial, patients were randomized to a once-daily oral dose of the AT1 receptor antagonist (1, 25, or 100 mg) or placebo after a placebo run-in period of 3 weeks. Randomization medication was given for 1 week. Compared with placebo, 24-hour ambulatory blood pressure did not change with the 1-mg dose, and it fell (mean and 95% confidence interval) by 7.0 (4.2-9.8)/6.1 (3.9-8.1) mm Hg with the 25-mg dose and by 12.1 (8.1-16.2)/7.2 (4.9-9.4) mm Hg with the 100-mg dose. Heart rate did not change during either dose. With the 25-mg dose, the antihypertensive effect was attenuated during the second half of the recording, and with the 100-mg dose, it was maintained for 24 hours. Baseline values of renin and the antihypertensive response to the 25- and 100-mg doses were well correlated (r = .68, P < .01). Renin did not change with the 1-mg dose, but it rose threefold to fourfold with the 25-mg dose and fourfold to fivefold with the 100-mg dose 4 to 6 hours after administration. With the 100-mg dose, renin was still elevated twofold 24 hours after dosing. The changes in renin induced by the AT1 receptor antagonist were associated with parallel increments in angiotensin I and angiotensin II. Aldosterone, despite AT1 receptor blockade, did not fall.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D002395 Catecholamines A general class of ortho-dihydroxyphenylalkylamines derived from TYROSINE. Catecholamine,Sympathin,Sympathins
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004573 Electrolytes Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed) Electrolyte
D005260 Female Females
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic

Related Publications

A H van den Meiracker, and P J Admiraal, and J A Janssen, and J M Kroodsma, and W A de Ronde, and F Boomsma, and J Sissmann, and P J Blankestijn, and P G Mulder, and A J Man In 't Veld
Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension.
August 2001, Gastroenterology,
A H van den Meiracker, and P J Admiraal, and J A Janssen, and J M Kroodsma, and W A de Ronde, and F Boomsma, and J Sissmann, and P J Blankestijn, and P G Mulder, and A J Man In 't Veld
Hypophagic effect of the angiotensin AT1 receptor antagonist irbesartan in rats.
June 2007, European journal of pharmacology,
A H van den Meiracker, and P J Admiraal, and J A Janssen, and J M Kroodsma, and W A de Ronde, and F Boomsma, and J Sissmann, and P J Blankestijn, and P G Mulder, and A J Man In 't Veld
Amelioration of cyclosporine nephrotoxicity by irbesartan, A selective AT1 receptor antagonist.
September 2004, Renal failure,
A H van den Meiracker, and P J Admiraal, and J A Janssen, and J M Kroodsma, and W A de Ronde, and F Boomsma, and J Sissmann, and P J Blankestijn, and P G Mulder, and A J Man In 't Veld
AT1-receptor antagonism in hypertension: what has been learned with irbesartan?
May 2003, Expert review of cardiovascular therapy,
A H van den Meiracker, and P J Admiraal, and J A Janssen, and J M Kroodsma, and W A de Ronde, and F Boomsma, and J Sissmann, and P J Blankestijn, and P G Mulder, and A J Man In 't Veld
Systemic and renal hemodynamic effects of the AT1 receptor antagonist, ZD 7155, and the AT2 receptor antagonist, PD 123319, in conscious lambs.
January 2007, Pflugers Archiv : European journal of physiology,
A H van den Meiracker, and P J Admiraal, and J A Janssen, and J M Kroodsma, and W A de Ronde, and F Boomsma, and J Sissmann, and P J Blankestijn, and P G Mulder, and A J Man In 't Veld
Regional hemodynamic effects of the AT1 receptor antagonist CV-11974 in conscious renal hypertensive rats.
December 1995, Hypertension (Dallas, Tex. : 1979),
A H van den Meiracker, and P J Admiraal, and J A Janssen, and J M Kroodsma, and W A de Ronde, and F Boomsma, and J Sissmann, and P J Blankestijn, and P G Mulder, and A J Man In 't Veld
Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques.
January 2000, Drug metabolism and disposition: the biological fate of chemicals,
A H van den Meiracker, and P J Admiraal, and J A Janssen, and J M Kroodsma, and W A de Ronde, and F Boomsma, and J Sissmann, and P J Blankestijn, and P G Mulder, and A J Man In 't Veld
AT1-receptor blockade: Protective effects of irbesartan in cardiomyocytes under hypoxic stress.
January 2018, PloS one,
A H van den Meiracker, and P J Admiraal, and J A Janssen, and J M Kroodsma, and W A de Ronde, and F Boomsma, and J Sissmann, and P J Blankestijn, and P G Mulder, and A J Man In 't Veld
Influence of the angiotensin II AT1 receptor antagonist irbesartan on ischemia/reperfusion injury in the dog heart.
October 2000, Basic research in cardiology,
A H van den Meiracker, and P J Admiraal, and J A Janssen, and J M Kroodsma, and W A de Ronde, and F Boomsma, and J Sissmann, and P J Blankestijn, and P G Mulder, and A J Man In 't Veld
[Irbesartan--a new AT1-receptor antagonist (AT1-blocker). Angiotensin-II-receptor antagonists: perspectives of a new therapeutic principle, Wiesbaden, 6 April 1997].
September 1997, Deutsche medizinische Wochenschrift (1946),
Copied contents to your clipboard!